Carcinogenesis, Vol. 21, No. 5, 953-958,
May 2000
© 2000 Oxford University Press
Molecular Epidemiology and Cancer Prevention |
Suppression of polypogenesis in a new mouse strain with a truncated Apc
474 by a novel COX-2 inhibitor, JTE-522
Pharmaceutical Frontier Research Laboratories, Japan Tobacco Inc., 1-13-2 Fukuura, Kanazawaku, Yokohama 236-4 and
1 Pharmaceutical/Biological Research Laboratories, Central Pharmaceutical Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-11, Japan
Mutations of the adenomatous polyposis coli gene (Apc) have been implicated in the occurrence of sporadic colon cancer. Various Apc knockout strains of mice have been created to better understand the function of this gene. In the present study, using gene targeting, we disrupted the mouse Apc gene at the end of exon 10 to compare its effect with the effects of other types of Apc gene disruption, all of which are on exon 15. The mice expressed a mutant form of mRNA that encoded 474 amino acids instead of 2845 amino acids due to exon duplication. In addition, these Apc
474 knockout mice developed intestinal and mammary tumors. Since the most severe cases of familial adenomatous polyposis are associated with mutations on exon 15, our mutation at exon 10 was expected to result in a mild phenotype. However, the number of polyps that our mice developed was similar to that of other Apc knockout mice such as ApcMin and Apc1309 mice. Cyclooxygenase-2 (COX-2) has been implicated in colorectal carcinoma. Apc474 mice treated with JTE-522, a novel COX-2-selective inhibitor, showed a significantly reduced number of polyps. These results suggest that COX-2 plays an important role in polypogenesis and COX-2-selective inhibitors can be used as new preventive therapeutics against colorectal tumors.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. V. Rao, H. Y. Yamada, Y. Yao, and W. Dai Enhanced genomic instabilities caused by deregulated microtubule dynamics and chromosome segregation: a perspective from genetic studies in mice Carcinogenesis, September 1, 2009; 30(9): 1469 - 1474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Misra, V. C. Hascall, C. De Giovanni, R. R. Markwald, and S. Ghatak Delivery of CD44 shRNA/Nanoparticles within Cancer Cells: PERTURBATION OF HYALURONAN/CD44v6 INTERACTIONS AND REDUCTION IN ADENOMA GROWTH IN Apc Min/+ MICE J. Biol. Chem., May 1, 2009; 284(18): 12432 - 12446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. T. Hawk and B. Levin Colorectal Cancer Prevention J. Clin. Oncol., January 10, 2005; 23(2): 378 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Kelloff, R. L. Schilsky, D. S. Alberts, R. W. Day, K. Z. Guyton, H. L. Pearce, J. C. Peck, R. Phillips, and C. C. Sigman Colorectal Adenomas: A Prototype for the Use of Surrogate End Points in the Development of Cancer Prevention Drugs Clin. Cancer Res., June 1, 2004; 10(11): 3908 - 3918. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Li, W. Qiao, L. Chen, X. Xu, X. Yang, D. Li, C. Li, S. G. Brodie, M. M. Meguid, L. Hennighausen, et al. Squamous cell carcinoma and mammary abscess formation through squamous metaplasia in Smad4/Dpc4 conditional knockout mice Development, December 15, 2003; 130(24): 6143 - 6153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Corpet and F. Pierre Point: From Animal Models to Prevention of Colon Cancer. Systematic Review of Chemoprevention in Min Mice and Choice of the Model System Cancer Epidemiol. Biomarkers Prev., May 1, 2003; 12(5): 391 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-i. Sunayama, H. Konno, T. Nakamura, H. Kashiwabara, T. Shoji, T. Tsuneyoshi, and S. Nakamura The role of cyclooxygenase-2 (COX-2) in two different morphological stages of intestinal polyps in APC{Delta}474 knockout mice Carcinogenesis, August 1, 2002; 23(8): 1351 - 1359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hida, K.-i. Kozaki, H. Ito, O. Miyaishi, Y. Tatematsu, T. Suzuki, K. Matsuo, T. Sugiura, M. Ogawa, T. Takahashi, et al. Significant Growth Inhibition of Human Lung Cancer Cells Both in Vitro and in Vivo by the Combined Use of a Selective Cyclooxygenase 2 Inhibitor, JTE-522, and Conventional Anticancer Agents Clin. Cancer Res., July 1, 2002; 8(7): 2443 - 2447. [Abstract] [Full Text] [PDF]
|
|